These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 3388475)
21. Intranasal DDAVP: biological and clinical evaluation in mild factor VIII deficiency. Chistolini A; Dragoni F; Ferrari A; La Verde G; Arcieri R; Ege Mohamud A; Mazzucconi MG Haemostasis; 1991; 21(5):273-7. PubMed ID: 1806455 [TBL] [Abstract][Full Text] [Related]
22. Accumulative effect of DDAVP and heparin in increasing plasma factor VIII levels. Rock G; Palmer DS Vox Sang; 1981; 41(1):56-60. PubMed ID: 6798759 [TBL] [Abstract][Full Text] [Related]
23. [Treatment of central diabetes insipidus using oral DDAVP. Comparison with intranasal treatment]. Carraro A; Fano M; Porcella E; Bernareggi V; Giusti M Minerva Endocrinol; 1991; 16(3):141-5. PubMed ID: 1806811 [TBL] [Abstract][Full Text] [Related]
24. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders. Nolan B; White B; Smith J; O'Reily C; Fitzpatrick B; Smith OP Br J Haematol; 2000 Jun; 109(4):865-9. PubMed ID: 10929043 [TBL] [Abstract][Full Text] [Related]
25. Effect of intranasal DDAVP in prevention of hypotension during hemodialysis. Beladi-Mousavi SS; Beladi-Mousavi M; Hayati F; Talebzadeh M Nefrologia; 2012; 32(1):89-93. PubMed ID: 22294007 [TBL] [Abstract][Full Text] [Related]
26. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Foster PA Thromb Haemost; 1995 Nov; 74(5):1370-8. PubMed ID: 8607125 [TBL] [Abstract][Full Text] [Related]
27. Subcutaneous and intranasal administration of 1-deamino-8-d-arginine vasopressin in the assessment of renal concentration capacity. Tryding N; Sterner G; Berg B; Harris A; Lundin S Nephron; 1987; 45(1):27-30. PubMed ID: 3808145 [TBL] [Abstract][Full Text] [Related]
28. [Characterization of FVIII/VW circulating after DDAVP administration (author's transl)]. Vicente V; Díez LF; Alberca I; San Miguel J; López Borrasca A An Esp Pediatr; 1981 Jun; 14(6):436-43. PubMed ID: 6794404 [TBL] [Abstract][Full Text] [Related]
29. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor. Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865 [TBL] [Abstract][Full Text] [Related]
30. Intranasal administration of demopressin (DDAVP) for type 1 and type 2A von Willebrand disease. Mohri H; Hashimoto Y; Yamazaki E; Kanamori H; Okubo T Hematopathol Mol Hematol; 1998; 11(2):109-15. PubMed ID: 9608359 [TBL] [Abstract][Full Text] [Related]
31. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). Köhler M; Hellstern P; Miyashita C; von Blohn G; Wenzel E Thromb Haemost; 1986 Feb; 55(1):108-11. PubMed ID: 3085261 [TBL] [Abstract][Full Text] [Related]
32. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease. Warrier AI; Lusher JM J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806 [TBL] [Abstract][Full Text] [Related]
33. Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators. Vicente V; Estellés A; Laso J; Moraleda JM; Rivera J; Aznar J Thromb Res; 1993 Apr; 70(2):117-22. PubMed ID: 8322282 [TBL] [Abstract][Full Text] [Related]
34. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease. Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368 [TBL] [Abstract][Full Text] [Related]
35. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female. Hilton P; Stanton SL Br J Urol; 1982 Jun; 54(3):252-5. PubMed ID: 7049302 [TBL] [Abstract][Full Text] [Related]
36. Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. Fjellestad-Paulsen A; Tubiana-Rufi N; Harris A; Czernichow P Acta Endocrinol (Copenh); 1987 Jul; 115(3):307-12. PubMed ID: 3618082 [TBL] [Abstract][Full Text] [Related]
37. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects. Takahashi H; Itoh M; Kobayashi I; Sakuragawa N; Shibata A Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902 [TBL] [Abstract][Full Text] [Related]
38. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461 [TBL] [Abstract][Full Text] [Related]
39. Simultaneous collection of platelets and cryoprecipitate by plasma-exchange donation. McLeod BC; Sassetti RJ; Owens EA; Scott JP Transfusion; 1989 May; 29(4):332-6. PubMed ID: 2497567 [TBL] [Abstract][Full Text] [Related]
40. Failure of posttrial administration of vasopressin analogue (DDAVP) to influence memory in healthy, young, male volunteers. Beckwith BE; Petros TV; Bergloff PJ; Swenson RR; Paulson R Peptides; 1995; 16(8):1327-8. PubMed ID: 8745039 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]